Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 10Phase 3 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 21Unknown 3Terminated 2Withdrawn 1Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × sargramostim × Clear all
NCT00089115 2013-08-02

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 3 Terminated
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00237575 2012-05-23

Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

University of Kentucky

Phase 3 Terminated
100 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡